A combination of ilixadencel plus first-line treatment with Sutent (sunitinib) prolonged overall survival to a clinically meaningful extent in newly diagnosed patients with metastatic renal cell carcinoma (mRCC), a form of kidney cancer, a Phase 2 trial found. People given this combo treatment in the MERECA trial (NCT02432846) lived 10 months longer than those on Sutent alone. While the study was not designed to determine a statistical difference in survival outcomes, this finding suggests that Immunicum’s…
You must be logged in to read/download the full post.
The post Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients appeared first on BioNewsFeeds.